Octaplaslg (Human Plasma Protein)

Human Plasma Protein, the active ingredient in Octaplaslg, is a plasma‑derived protein supplement presented as a lyophilized powder for intravenous use. It is employed to replace deficient plasma proteins in patients with bleeding disorders, massive transfusion, or liver disease.

GNH USA supplies Octaplaslg as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to healthcare institutions across multiple regions. Its distribution network ensures timely delivery and compliance with local import requirements.

Octaplaslg, a plasma‑derived protein supplement, is used to support hemostasis and volume replacement in several clinical settings. - Massive transfusion: provides balanced plasma proteins to restore coagulation factors and maintain intravascular volume. - Liver disease-associated coagulopathy: supplies deficient clotting factors to improve hemostatic balance. - Congenital factor deficiencies: replaces missing plasma proteins in patients with rare clotting factor disorders. - Surgical bleeding management: delivers plasma proteins to control intra‑operative hemorrhage and support postoperative recovery.

Octaplaslg may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Fever: transient elevation of body temperature following infusion. - Chills: shivering episodes during or shortly after administration. - Headache: mild to moderate head discomfort. - Nausea: feeling of sickness or urge to vomit. - Allergic rash: localized skin redness or urticaria. - Hypotension: mild drop in blood pressure during infusion.

Serious or Rare Side Effects: - Anaphylaxis: severe, potentially life‑threatening allergic reaction. - Transfusion‑related acute lung injury (TRALI): acute respiratory distress after infusion. - Viral transmission: theoretical risk of pathogen transmission despite screening. - Hemolysis: destruction of red blood cells leading to anemia. - Volume overload: circulatory strain causing pulmonary edema. - Thromboembolic events: formation of clots causing vascular occlusion.

When using Octaplaslg, healthcare professionals should observe several precautionary measures to ensure patient safety. - Patient assessment: verify plasma protein deficiency and clinical indication before administration. - Allergy screening: check for known hypersensitivity to plasma proteins or IgA deficiency. - Infection control: confirm that the product batch has passed viral inactivation and pathogen testing. - Fluid balance monitoring: observe for signs of volume overload, especially in cardiac or renal compromise. - Coagulation monitoring: regularly assess PT, aPTT, and factor levels during therapy. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Octaplaslg can interact with other therapies; awareness of these interactions helps manage risks.

Major Interactions (Avoid): - Anticoagulants (e.g., warfarin, heparin): may diminish the intended hemostatic benefit of the plasma product. - IgA‑deficient patients with anti‑IgA antibodies: risk of severe anaphylactic reaction. - High‑dose vitamin K antagonists: concurrent use can lead to unpredictable coagulation responses.

Moderate Interactions (Monitor Closely): - Diuretics: may exacerbate fluid shifts; monitor electrolytes and volume status. - Concurrent blood component therapy: increased risk of volume overload; adjust infusion rates. - Immunosuppressants: heightened infection risk; observe for signs of infection.